How should informed consent evolve for gene editing?

Rapid advances in CRISPR and related gene editing tools have outpaced traditional models of informed consent, creating a need to reframe consent not only as an individual transaction but as an ongoing, socially embedded process. Jennifer Doudna at University of California Berkeley and Emmanuelle Charpentier at Max Planck Institute, who pioneered CRISPR, have emphasized ethical responsibility alongside technical development. New clinical uses of somatic editing and the prospect of heritable germline alterations raise distinctive questions about who can give consent, what information is meaningful, and how consent must adapt to uncertainties about long-term effects and cross-border research.

Consent beyond the individual

Germline interventions highlight a fundamental problem: future persons affected by genetic changes cannot themselves consent. Françoise Baylis at Dalhousie University has argued that this intergenerational dimension challenges the core premises of informed consent and requires supplementary governance mechanisms that respect the rights of those not yet born. Cultural and territorial contexts complicate this further. Indigenous communities and other groups with collective decision-making traditions may require consultation models that go beyond individual assent, and historical abuses in medical research have left some communities with heightened mistrust. Recognizing community-level values and sovereignty is therefore essential when editing genomes that could affect an entire population or ecosystem.

Practical steps for evolving consent

Scholarly and institutional guidance points toward several complementary changes. The World Health Organization recommends global oversight structures and transparent public engagement to build trust and harmonize standards. The National Academies of Sciences, Engineering, and Medicine advocate for rigorous oversight, long-term follow-up, and mechanisms to ensure researchers communicate uncertainties and plan for monitoring. Clinically, consent should be iterative and dynamic, offering participants updated information as new risks or outcomes emerge and enabling withdrawal of participation in ongoing research components where possible. Patient-centered explanations must cover not only immediate medical risks and benefits but also social implications such as privacy, potential for discrimination, and data sharing.

Consequences of failing to evolve consent are significant. Individuals and communities may experience harm from unanticipated biological effects or from social fallout such as stigmatization and loss of autonomy. Environmental interventions like gene drives carry territorial consequences when altered organisms cross political borders, raising issues of international law and ecological stewardship. Researchers such as Kevin Esvelt at Massachusetts Institute of Technology have highlighted ecological risks and the need for broad, inclusive deliberation before deployment.

Adapting consent for gene editing therefore requires combining robust individual consent with community engagement, long-range monitoring, and multilayered governance. Practical implementation will demand investment in ethics capacity, culturally competent communication, and legal frameworks that protect future generations and the environment while enabling responsible innovation. When institutions build consent processes that acknowledge uncertainty, cultural diversity, and ecological interdependence, they strengthen legitimacy and reduce the likelihood of harm.